BRPI0516177B8 - oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 - Google Patents

oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53

Info

Publication number
BRPI0516177B8
BRPI0516177B8 BRPI0516177A BRPI0516177A BRPI0516177B8 BR PI0516177 B8 BRPI0516177 B8 BR PI0516177B8 BR PI0516177 A BRPI0516177 A BR PI0516177A BR PI0516177 A BRPI0516177 A BR PI0516177A BR PI0516177 B8 BRPI0516177 B8 BR PI0516177B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
patient
compound
oligoribonucleotides
decreasing
Prior art date
Application number
BRPI0516177A
Other languages
English (en)
Portuguese (pt)
Inventor
Zurr Daniel
Feinstein Elena
Ehrlich Shai
Original Assignee
Quark Biotech Inc
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc, Quark Pharmaceuticals Inc filed Critical Quark Biotech Inc
Publication of BRPI0516177A publication Critical patent/BRPI0516177A/pt
Publication of BRPI0516177B1 publication Critical patent/BRPI0516177B1/pt
Publication of BRPI0516177B8 publication Critical patent/BRPI0516177B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0516177A 2004-09-28 2005-09-27 oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 BRPI0516177B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61399104P 2004-09-28 2004-09-28
US65819605P 2005-03-02 2005-03-02
US70302005P 2005-07-26 2005-07-26
PCT/IL2005/001035 WO2006035434A2 (en) 2004-09-28 2005-09-27 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases

Publications (3)

Publication Number Publication Date
BRPI0516177A BRPI0516177A (pt) 2008-08-26
BRPI0516177B1 BRPI0516177B1 (pt) 2019-01-08
BRPI0516177B8 true BRPI0516177B8 (pt) 2021-05-25

Family

ID=36119277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516177A BRPI0516177B8 (pt) 2004-09-28 2005-09-27 oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53

Country Status (19)

Country Link
US (5) US8765699B2 (enExample)
EP (1) EP1799269B1 (enExample)
JP (3) JP4991547B2 (enExample)
KR (2) KR101409241B1 (enExample)
CN (1) CN102643818B (enExample)
AU (1) AU2005288522B2 (enExample)
BR (1) BRPI0516177B8 (enExample)
CA (1) CA2580126C (enExample)
DK (1) DK1799269T3 (enExample)
ES (1) ES2594083T3 (enExample)
HU (1) HUE030844T2 (enExample)
LT (1) LT1799269T (enExample)
MX (2) MX2007003795A (enExample)
NZ (1) NZ553987A (enExample)
PL (1) PL1799269T3 (enExample)
PT (1) PT1799269T (enExample)
RU (1) RU2584609C2 (enExample)
SG (1) SG161307A1 (enExample)
WO (1) WO2006035434A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219569A1 (en) * 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
JP5118285B2 (ja) * 2000-06-20 2013-01-16 大日本住友製薬株式会社 オリゴヌクレオチド導入製剤
ATE429930T1 (de) * 2001-06-20 2009-05-15 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20050250724A1 (en) * 2004-04-13 2005-11-10 Boston Biomedical Research Institute Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death
US8361976B2 (en) 2004-07-09 2013-01-29 University Of Massachusetts Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
MX2007002043A (es) 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
RU2584609C2 (ru) 2004-09-28 2016-05-20 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности
JP4131271B2 (ja) * 2005-03-30 2008-08-13 ソニー株式会社 情報処理装置および方法、並びにプログラム
US20070135368A1 (en) * 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
CA2665202A1 (en) * 2006-10-02 2008-04-10 Aprea Ab Compounds and methods
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
DE102007008596B4 (de) * 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
WO2008126085A2 (en) * 2007-04-12 2008-10-23 Quark Pharmaceuticals, Inc. Method for treating bone marrow disorders
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
PT2170403E (pt) * 2007-06-27 2014-07-17 Quark Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes pró-apoptóticos
US8614309B2 (en) * 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2009074990A2 (en) * 2007-12-12 2009-06-18 Quark Pharmaceuticals, Inc. Rtp801l sirna compounds and methods of use thereof
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc COMPOUNDS AND USES THEREOF
EP2293800B1 (en) * 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
JP2012517815A (ja) * 2009-02-18 2012-08-09 サイレンス・セラピューティクス・アーゲー Ａｎｇ２の発現を阻害するための手段
JP2012529430A (ja) * 2009-06-08 2012-11-22 クォーク ファーマシューティカルズ インコーポレーティッド 慢性腎臓疾患の治療方法
CA2772336A1 (en) * 2009-08-28 2011-03-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DK3252068T3 (da) * 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
AU2011338682B2 (en) * 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
CN104271740A (zh) 2011-04-20 2015-01-07 L·J·史密斯 利用在细胞中自组装和产生RNAi活性的成分来调节基因表达的方法和组合物
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
CN103145845A (zh) * 2011-12-06 2013-06-12 吉林圣元科技有限责任公司 Tat与人野生型P53融合蛋白在毕赤酵母中的表达
US10081809B2 (en) 2012-04-18 2018-09-25 University Of Miami Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
EP2895608B1 (en) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
MX373950B (es) 2014-05-29 2020-07-13 Quark Pharmaceuticals Inc USO DE UN INHIBIDOR TEMPORAL DE UN GEN p53 PARA LA PROFILAXIS DE LESIÓN POR ISQUEMIA-REPERFUSIÓN.
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
EP3737388A4 (en) * 2018-01-12 2021-10-06 University of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
CA2028756A1 (en) 1989-11-24 1991-05-25 Alfons H. M. Raeymaekers Immunostimulating 6-aryl-5,6-dihydro-imidazo[2,1-b]thiazole derivatives
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
AU662298B2 (en) 1990-09-20 1995-08-31 Gilead Sciences, Inc. Modified internucleoside linkages
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
GB9608937D0 (en) * 1996-04-29 1996-07-03 Cancer Res Campaign Tech Screening methods for therapeutics and peptides used in the screen
WO2005121370A2 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Oligomeric compounds that facilitate risc loading
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5849774A (en) * 1996-07-03 1998-12-15 University Of Pittsburgh Treatment of sepsis-induced acute renal failure
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999055910A1 (en) 1998-04-24 1999-11-04 Arizona Board Of Regents Method of inducing apoptosis in a target cell
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
CA2352486A1 (en) * 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
CA2360671A1 (en) 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and therapeutic use of the same
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
WO2001068336A2 (en) 2000-03-16 2001-09-20 Generis Gmbh Method for manufacturing a structural part by a deposition technique
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
EP1354038A2 (en) 2000-12-28 2003-10-22 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
EP2455467B1 (en) * 2002-02-01 2016-10-05 Life Technologies Corporation Double-stranded oligonucleotides
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
DK1527176T4 (en) * 2002-08-05 2017-07-03 Silence Therapeutics Gmbh ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
CN1780603A (zh) * 2002-08-27 2006-05-31 雀巢制品公司 预防或治疗上皮组织损伤或毛发脱落
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044136A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
PT1633767T (pt) 2003-06-02 2019-02-27 Univ Massachusetts Métodos e composições para controlar a eficácia do silenciamento de arn
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
WO2005107793A2 (en) * 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US7428919B2 (en) 2004-08-02 2008-09-30 Young David P Method and system for evaluating fluid flow through a heat exchanger
MX2007002043A (es) 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
RU2584609C2 (ru) 2004-09-28 2016-05-20 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20070259827A1 (en) 2006-01-25 2007-11-08 University Of Massachusetts Compositions and methods for enhancing discriminatory RNA interference
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
PT2170403E (pt) 2007-06-27 2014-07-17 Quark Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes pró-apoptóticos

Also Published As

Publication number Publication date
WO2006035434A3 (en) 2009-04-23
US20120184597A1 (en) 2012-07-19
WO2006035434A2 (en) 2006-04-06
JP4991547B2 (ja) 2012-08-01
AU2005288522B2 (en) 2012-06-28
MX2007003795A (es) 2007-07-11
BRPI0516177A (pt) 2008-08-26
CN102643818B (zh) 2014-04-09
US20090082291A1 (en) 2009-03-26
JP2008514223A (ja) 2008-05-08
RU2011130434A (ru) 2013-01-27
RU2584609C2 (ru) 2016-05-20
PL1799269T3 (pl) 2017-01-31
US7842674B2 (en) 2010-11-30
JP2012152216A (ja) 2012-08-16
LT1799269T (lt) 2016-10-25
ES2594083T3 (es) 2016-12-15
US8148342B2 (en) 2012-04-03
JP2014236738A (ja) 2014-12-18
BRPI0516177B1 (pt) 2019-01-08
US8765699B2 (en) 2014-07-01
AU2005288522A1 (en) 2006-04-06
KR20130006547A (ko) 2013-01-16
SG161307A1 (en) 2010-05-27
US20060069056A1 (en) 2006-03-30
HUE030844T2 (en) 2017-06-28
KR20070083764A (ko) 2007-08-24
US20150141487A1 (en) 2015-05-21
DK1799269T3 (en) 2016-10-03
NZ553987A (en) 2011-01-28
EP1799269B1 (en) 2016-09-07
EP1799269A4 (en) 2012-01-18
MX336710B (es) 2016-01-28
US20080287382A1 (en) 2008-11-20
CA2580126C (en) 2014-08-26
KR101357016B1 (ko) 2014-02-03
CN102643818A (zh) 2012-08-22
CA2580126A1 (en) 2006-04-06
PT1799269T (pt) 2016-10-04
JP5952350B2 (ja) 2016-07-13
US9334499B2 (en) 2016-05-10
KR101409241B1 (ko) 2014-06-24
EP1799269A2 (en) 2007-06-27
US9006196B2 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
BRPI0516177B8 (pt) oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53
Azambuja et al. CD73 downregulation decreases in vitro and in vivo glioblastoma growth
Izetti et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
Chun et al. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways
Tsou et al. Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP+ toxicity
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BRPI0622054B8 (pt) composto e composição farmacêutica
MX348817B (es) Metodos para tratar cancer y estados no neoplasicos.
Spartalis et al. Histone deacetylase inhibitors and anaplastic thyroid carcinoma
WO2007089945A3 (en) Treating diseases by targeting silt3
WO2008063318A3 (en) Betulinic acid, derivatives and analogs thereof and uses therefor
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
Zhang et al. Methyl helicterate inhibits hepatic stellate cell activation through modulation of apoptosis and autophagy
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
JP2020055884A (ja) がんのためのグルフォスファミド組み合わせ療法
BRPI0810384B8 (pt) terapia enzimática anticâncer
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: QUARK PHARMACEUTICALS, INC. (US)

Free format text: ALTERADO DE: QUARK BIOTECH, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2741 DE 18-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.